# Kenneth Offit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5962809/publications.pdf

Version: 2024-02-01

| | | 1704 | 3487 |
|---|---|---|---|
| 381 | 39,831 | 104 | 182 |
| papers | citations | h-index | g-index |

| | | | |
|---|---|---|---|
| 395 | 395 | 395 | 35172 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. BMJ Open, 2022, 8, e021876. | 1.9 | 22 |
| 2 | Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122. | 6.3 | 19 |
| 3 | Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209. | 2.9 | 34 |
| 4 | Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371. | 2.5 | 7 |
| 5 | Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250. | 1.9 | 40 |
| 6 | Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575. | 2.4 | 8 |
| 7 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362. | 2.8 | 23 |
| 8 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2. | 5.0 | 15 |
| 9 | Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195. | 2.4 | 7 |
| 10 | Cancer-Causative Mutations Occurring in Early Embryogenesis. Cancer Discovery, 2022, 12, 949-957. | 9.4 | 21 |
| 11 | SNPs at SMG7 associated with time from biochemical recurrence to prostate cancer death. Cancer Epidemiology Biomarkers and Prevention, 2022, , . | 2.5 | 1 |
| 12 | Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6. | 1.3 | 36 |
| 13 | Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437. | 7.0 | 23 |
| 14 | Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010. | 7.0 | 15 |
| 15 | Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502. | 4.7 | 27 |
| 16 | Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217. | | 0 |
| 17 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078. | 12.8 | 19 |
| 18 | Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334. | 12.1 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365. | 13.2 | 74 |
| 20 | Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465. | 3.0 | 10 |
| 21 | Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153. | 2.9 | 2 |
| 22 | Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529. | 6.2 | 5 |
| 23 | The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. Genetics in Medicine, 2021, 23, 1086-1094. | 2.4 | 18 |
| 24 | Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1336-1348. | 2.5 | 15 |
| 25 | Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. Neuron, 2021, 109, 1465-1478.e4. | 8.1 | 21 |
| 26 | The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737. | 2.4 | 16 |
| 27 | Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753. | 5.9 | 15 |
| 28 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203. | 6.2 | 6 |
| 29 | Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , . | 6.3 | 6 |
| 30 | Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113. | 2.4 | 29 |
| 31 | A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692. | 6.3 | 66 |
| 32 | Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709. | 1.6 | 83 |
| 33 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145. | 6.4 | 9 |
| 34 | Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecologic Oncology, 2021, 162, 506-516. | 1.4 | 39 |
| 35 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102. | 4.9 | 498 |
| 36 | Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135. | 5.2 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000. | 5.4 | 16 |
| 38 | Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975. | 12.8 | 81 |
| 39 | Facilitated cascade testing (FaCT): a randomized controlled trial. International Journal of Gynecological Cancer, 2021, 31, 779-783. | 2.5 | 6 |
| 40 | The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585. | 21.4 | 44 |
| 41 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638. | 0.9 | 39 |
| 42 | Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. Human Molecular Genetics, 2020, 29, 70-79. | 2.9 | 17 |
| 43 | Genetic Factors. , 2020, , 180-208.e11. | | 4 |
| 44 | Fumarate hydrataseFHc.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109. | 2.5 | 25 |
| 45 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73. | 21.4 | 120 |
| 46 | Cumulative Burden of Colorectal Cancerâ€"Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12. | 1.3 | 110 |
| 47 | Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20. | 1.3 | 90 |
| 48 | Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 477-486. | 2.5 | 25 |
| 49 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685. | 1.6 | 270 |
| 50 | Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. Genetics in Medicine, 2020, 22, 727-735. | 2.4 | 34 |
| 51 | Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414. | 1.6 | 60 |
| 52 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666. | 2.4 | 82 |
| 53 | A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744. | 0.9 | 32 |
| 54 | Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444. | 6.2 | 124 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226. | 21.4 | 367 |
| 56 | Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC Medicine, 2020, 18, 229. | 5.5 | 28 |
| 57 | Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. Journal of Thoracic Oncology, 2020, 15, 1871-1879. | 1.1 | 24 |
| 58 | Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925. | 3.0 | 9 |
| 59 | Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396. | 5.5 | 76 |
| 60 | Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010. | 1.7 | 3 |
| 61 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581. | 21.4 | 265 |
| 62 | Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220. | 12.8 | 31 |
| 63 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688. | 3.3 | 2 |
| 64 | Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <b><i>BRCA1/2</i></b> Genetic Risk Modifier Test. Public Health Genomics, 2020, 23, 6-19. | 1.0 | 7 |
| 65 | Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218. | 7.1 | 48 |
| 66 | Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468. | 1.3 | 32 |
| 67 | Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408. | 1.6 | 60 |
| 68 | Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. Journal of Clinical Oncology, 2020, 38, 1389-1397. | 1.6 | 48 |
| 69 | 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer, 2020, 126, 3114-3121. | 4.1 | 23 |
| 70 | Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597. | 12.8 | 193 |
| 71 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391. | 4.9 | 314 |
| 72 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157. | 6.3 | 129 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863. | 1.3 | 28 |
| 74 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764. | 1.9 | 80 |
| 75 | Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579. | 27.8 | 295 |
| 76 | Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5. | 3.0 | 2 |
| 77 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38. | 5.2 | 28 |
| 78 | Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524. | 3.3 | 5 |
| 79 | Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431. | 12.8 | 88 |
| 80 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192. | 6.4 | 19 |
| 81 | BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796. | 2.5 | 26 |
| 82 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741. | 12.8 | 90 |
| 83 | CHEK2 Alleles Predispose to Renal Cancer in Polandâ€”In Reply. JAMA Oncology, 2019, 5, 576. | 7.1 | 1 |
| 84 | Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295. | 1.6 | 397 |
| 85 | Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 2019, 138, 307-326. | 3.8 | 44 |
| 86 | Toward automation of germline variant curation in clinical cancer genetics. Genetics in Medicine, 2019, 21, 2116-2125. | 2.4 | 27 |
| 87 | Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open, 2019, 9, e031092. | 1.9 | 10 |
| 88 | Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15. | 3.0 | 7 |
| 89 | Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prevention Research, 2019, 12, 599-608. | 1.5 | 6 |
| 90 | Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046. | 5.2 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). Journal of Physical Education and Sports Management, 2019, 5, a004739. | 1.2 | 14 |
| 92 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34. | 6.2 | 711 |
| 93 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364. | 6.3 | 30 |
| 94 | Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. Genetics in Medicine, 2019, 21, 1507-1516. | 2.4 | 19 |
| 95 | Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genetics in Medicine, 2019, 21, 1497-1506. | 2.4 | 52 |
| 96 | Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87. | 21.4 | 377 |
| 97 | Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539. | 2.8 | 6 |
| 98 | A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327. | 2.4 | 31 |
| 99 | Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074. | 6.3 | 170 |
| 100 | Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620. | 2.5 | 224 |
| 101 | The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. European Journal of Human Genetics, 2018, 26, 984-995. | 2.8 | 42 |
| 102 | High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355. | 3.8 | 24 |
| 103 | Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759. | 0.9 | 56 |
| 104 | BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752. | 3.5 | 148 |
| 105 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182. | 12.8 | 15 |
| 106 | Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Human Mutation, 2018, 39, 1542-1552. | 2.5 | 40 |
| 107 | Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228. | 7.1 | 132 |
| 108 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430. | 0.9 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096. | 0.9 | 34 |
| 110 | Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584. | 1.2 | 33 |
| 111 | Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504. | 1.6 | 2 |
| 112 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111. | 3.5 | 30 |
| 113 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438. | 2.8 | 26 |
| 114 | Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306. | 2.5 | 16 |
| 115 | Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Cancer, 2017, 123, 2452-2458. | 4.1 | 12 |
| 116 | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175. | 12.8 | 75 |
| 117 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20. | 4.9 | 408 |
| 118 | The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22. | 5.2 | 108 |
| 119 | Multigene Testing for Hereditary Cancer: When, Why, and How. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 741-743. | 4.9 | 7 |
| 120 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691. | 21.4 | 356 |
| 121 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778. | 21.4 | 289 |
| 122 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825. | 7.4 | 366 |
| 123 | Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303. | 27.8 | 685 |
| 124 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187. | 2.7 | 15 |
| 125 | Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925. | 1.2 | 17 |
| 126 | Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33. | 1.5 | 111 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134. | 2.5 | 18 |
| 128 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135. | 2.5 | 278 |
| 129 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, . | 6.3 | 242 |
| 130 | Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. JCO Precision Oncology, 2017, 1, 1-13. | 3.0 | 6 |
| 131 | Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. Journal of Oncology Practice, 2017, 13, e590-e601. | 2.5 | 27 |
| 132 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16. | 3.0 | 286 |
| 133 | Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263. | 1.6 | 1 |
| 134 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250. | 1.6 | 152 |
| 135 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801. | 2.5 | 10 |
| 136 | Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434. | 7.1 | 189 |
| 137 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453. | 27.0 | 1,205 |
| 138 | Twentyâ€oneâ€“gene recurrence score assay in <scp>BRCA</scp>â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184. | 4.1 | 42 |
| 139 | Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 153-162. | 4.9 | 153 |
| 140 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64. | 5.0 | 31 |
| 141 | Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147. | 1.6 | 204 |
| 142 | Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817. | 6.2 | 113 |
| 143 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15. | 5.0 | 88 |
| 144 | Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078. | 1.6 | 147 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275. | 9.4 | 41 |
| 146 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112. | 5.0 | 42 |
| 147 | The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622. | 2.2 | 23 |
| 148 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375. | 12.8 | 93 |
| 149 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675. | 12.8 | 78 |
| 150 | Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456. | 2.5 | 16 |
| 151 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933. | 12.8 | 94 |
| 152 | Age- and Tumor Subtypeâ€“Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760. | 1.6 | 152 |
| 153 | Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588. | 27.6 | 258 |
| 154 | Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104. | 7.1 | 270 |
| 155 | Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785. | 1.0 | 38 |
| 156 | Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676. | 2.9 | 52 |
| 157 | Genomic Biomarkers for Breast Cancer Risk. Advances in Experimental Medicine and Biology, 2016, 882, 1-32. | 1.6 | 42 |
| 158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386. | 21.4 | 125 |
| 159 | Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e1-238.e7. | 1.6 | 20 |
| 160 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315. | 6.3 | 77 |
| 161 | Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Briefings in Bioinformatics, 2016, 17, 672-677. | 6.5 | 6 |
| 162 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401. | 1.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology, 2016, 34, e61-e67. | 1.6 | 6 |
| 164 | Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. Journal of Clinical Oncology, 2016, 34, 1518-1518. | 1.6 | 3 |
| 165 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61. | 5.0 | 26 |
| 166 | Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279. | 6.3 | 152 |
| 167 | Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388. | 4.1 | 167 |
| 168 | Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020. | 2.5 | 34 |
| 169 | Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genetics, 2015, 11, e1005262. | 3.5 | 128 |
| 170 | A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751. | 12.8 | 58 |
| 171 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, . | 6.3 | 428 |
| 172 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607. | 2.9 | 40 |
| 173 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171. | 21.4 | 221 |
| 174 | FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355. | 2.9 | 91 |
| 175 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347. | 7.4 | 390 |
| 176 | Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316. | 2.5 | 22 |
| 177 | Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. PLoS ONE, 2015, 10, e0139360. | 2.5 | 5 |
| 178 | Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk. Frontiers in Genetics, 2014, 5, 29. | 2.3 | 13 |
| 179 | Clinical features and management of em BRCA1 em and em BRCA2- em associated prostate cancer. Frontiers in Bioscience - Elite, 2014, E6, 15-30. | 1.8 | 21 |
| 180 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256. | 3.5 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416. | 5.0 | 57 |
| 182 | Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention. Science, 2014, 343, 1466-1470. | 12.6 | 300 |
| 183 | A decade of discovery in cancer genomics. Nature Reviews Clinical Oncology, 2014, 11, 632-634. | 27.6 | 17 |
| 184 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238. | 21.4 | 147 |
| 185 | Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471. | 6.2 | 96 |
| 186 | Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698. | 1.6 | 121 |
| 187 | Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835. | 12.8 | 156 |
| 188 | Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment, 2014, 145, 625-634. | 2.5 | 11 |
| 189 | Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1326-1338. | 4.9 | 119 |
| 190 | Genetic Variation in DNA Repair Pathways and Risk of Non-Hodgkin's Lymphoma. PLoS ONE, 2014, 9, e101685. | 2.5 | 19 |
| 191 | Genetic Factors. , 2014, , 169-187.e7. | | 4 |
| 192 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Research, 2013, 15, 402. | 5.0 | 36 |
| 193 | Revealing the Incidentalome When Targeting the Tumor Genome. JAMA - Journal of the American Medical Association, 2013, 310, 795. | 7.4 | 60 |
| 194 | A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231. | 21.4 | 270 |
| 195 | Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genetics in Medicine, 2013, 15, 721-728. | 2.4 | 40 |
| 196 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384. | 21.4 | 493 |
| 197 | Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876. | 21.4 | 179 |
| 198 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279. | 2.5 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173. | 3.5 | 105 |
| 200 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 3.5 | 244 |
| 201 | Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. PLoS Genetics, 2013, 9, e1003220. | 3.5 | 44 |
| 202 | Evidence of Geneâ€“Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284. | 3.5 | 136 |
| 203 | Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?. Journal of Clinical Oncology, 2013, 31, 1267-1270. | 1.6 | 217 |
| 204 | Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348. | 4.1 | 58 |
| 205 | Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 2743-2748. | 1.6 | 60 |
| 206 | Translating Genomics in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1343-1353. | 4.9 | 63 |
| 207 | Genome-wide association studies of cancer predisposition. , 2013, , 10-20. | | 1 |
| 208 | Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961. | 2.5 | 37 |
| 209 | Risks to Relatives in Genomic Research: A Duty to Warn?. American Journal of Bioethics, 2012, 12, 12-14. | 0.9 | 19 |
| 210 | A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370. | 2.5 | 23 |
| 211 | Heterozygous Mutations in DNA Repair Genes and Hereditary Breast Cancer: A Question of Power. PLoS Genetics, 2012, 8, e1003008. | 3.5 | 13 |
| 212 | Association of aHOXB13Variant with Breast Cancer. New England Journal of Medicine, 2012, 367, 480-481. | 27.0 | 21 |
| 213 | Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657. | 2.5 | 47 |
| 214 | Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147. | 2.5 | 513 |
| 215 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302. | 2.5 | 4 |
| 216 | Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620. | 3.2 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383. | 6.2 | 21 |
| 218 | Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706. | 2.5 | 11 |
| 219 | Improved survival for BRCA2â€associated serous ovarian cancer compared with both BRCAâ€negative and BRCA1â€associated serous ovarian cancer. Cancer, 2012, 118, 3703-3709. | 4.1 | 72 |
| 220 | Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations. Cancer, 2012, 118, 6270-6277. | 4.1 | 30 |
| 221 | Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry. Human Genetics, 2012, 131, 1173-1185. | 3.8 | 14 |
| 222 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126. | 2.5 | 8 |
| 223 | Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. Journal of the American College of Surgeons, 2012, 214, 61-67. | 0.5 | 32 |
| 224 | GermlineBRCAmutation does not prevent response to taxaneâ€based therapy for the treatment of castrationâ€resistant prostate cancer. BJU International, 2012, 109, 713-719. | 2.5 | 40 |
| 225 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33. | 5.0 | 78 |
| 226 | Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499. | 4.1 | 83 |
| 227 | Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702. | 2.5 | 34 |
| 228 | Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380. | 2.5 | 51 |
| 229 | Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021. | 21.4 | 662 |
| 230 | Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics, 2011, 48, 523-525. | 3.2 | 28 |
| 231 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110. | 5.0 | 71 |
| 232 | Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism: Clinical and Experimental, 2011, 60, 1234-1243. | 3.4 | 51 |
| 233 | Genetics, genomics, and cancer risk assessment. Ca-A Cancer Journal for Clinicians, 2011, 61, 327-359. | 329.8 | 172 |
| 234 | BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. Breast Cancer Research and Treatment, 2011, 130, 1051-1056. | 2.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699. | 3.8 | 18 |
| 236 | Personalized medicine: new genomics, old lessons. Human Genetics, 2011, 130, 3-14. | 3.8 | 173 |
| 237 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321. | 2.9 | 68 |
| 238 | Including Additional Controls from Public Databases Improves the Power of a Genome-Wide Association Study. Human Heredity, 2011, 72, 21-34. | 0.8 | 17 |
| 239 | Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116. | 6.3 | 40 |
| 240 | Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199. | 5.6 | 91 |
| 241 | Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594. | 4.9 | 253 |
| 242 | Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Research and Treatment, 2010, 123, 581-585. | 2.5 | 15 |
| 243 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892. | 21.4 | 309 |
| 244 | American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2010, 28, 893-901. | 1.6 | 389 |
| 245 | Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754. | 0.9 | 169 |
| 246 | Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer. Cancer Prevention Research, 2010, 3, 611-619. | 1.5 | 60 |
| 247 | New Pharmacogenomic Paradigm in Breast Cancer Treatment. Journal of Clinical Oncology, 2010, 28, 4665-4666. | 1.6 | 14 |
| 248 | Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121. | 7.0 | 263 |
| 249 | Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183. | 3.5 | 85 |
| 250 | Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. Clinical Cancer Research, 2010, 16, 2819-2832. | 7.0 | 74 |
| 251 | Diagnosing Hereditary Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 205-211. | 2.3 | 12 |
| 252 | Genome-wide Association Studies of Cancer Predisposition. Hematology/Oncology Clinics of North America, 2010, 24, 973-996. | 2.2 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Genome-Wide Association Studies of Cancer. Journal of Clinical Oncology, 2010, 28, 4255-4267. | 1.6 | 159 |
| 254 | Ethicolegal Aspects of Cancer Genetics. Cancer Treatment and Research, 2010, 155, 1-14. | 0.5 | 8 |
| 255 | Inherited Predisposition to Cancer: Introduction and Overview. Hematology/Oncology Clinics of North America, 2010, 24, 793-797. | 2.2 | 7 |
| 256 | Breast Cancer Single-Nucleotide Polymorphisms: Statistical Significance and Clinical Utility. Journal of the National Cancer Institute, 2009, 101, 973-975. | 6.3 | 13 |
| 257 | Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10236-10241. | 7.1 | 62 |
| 258 | The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2468-2475. | 2.5 | 22 |
| 259 | BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2009, 27, 433-438. | 1.6 | 194 |
| 260 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456. | 2.9 | 99 |
| 261 | Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14920-14925. | 7.1 | 59 |
| 262 | cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 663, 84-89. | 1.0 | 9 |
| 263 | A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nature Genetics, 2009, 41, 455-459. | 21.4 | 322 |
| 264 | The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Healthâ€“Centers for Disease Control and Prevention Multidisciplinary Workshop. Genetics in Medicine, 2009, 11, 559-567. | 2.4 | 207 |
| 265 | A Rapid and Reliable Test for BRCA1 and BRCA2 Founder Mutation Analysis in Paraffin Tissue Using Pyrosequencing. Journal of Molecular Diagnostics, 2009, 11, 176-181. | 2.8 | 18 |
| 266 | Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. American Journal of Surgical Pathology, 2009, 33, 1639-1645. | 3.7 | 155 |
| 267 | Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics, 2008, 9, 14. | 2.7 | 31 |
| 268 | Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal of Surgical Oncology, 2008, 97, 621-625. | 1.7 | 9 |
| 269 | Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters, 2008, 270, 173-180. | 7.2 | 19 |
| 270 | Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4340-4345. | 7.1 | 274 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Variants of the Adiponectin (<emph type="ital">ADIPOQ</emph>) and Adiponectin Receptor 1 (<emph type="ital">ADIPOR1</emph>) Genes and Colorectal Cancer Risk. JAMA - Journal of the American Medical Association, 2008, 300, 1523. | 7.4 | 127 |
| 272 | Genomic Profiles for Disease Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1353. | 7.4 | 100 |
| 273 | Ethical and Legal Implications of Cancer Genetic Testing: Do Physicians Have a Duty to Warn Patients' Relatives About Possible Genetic Risks?. Journal of Oncology Practice, 2008, 4, 229-230. | 2.5 | 18 |
| 274 | Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337. | 1.6 | 522 |
| 275 | Time to Check CHEK2 in Families With Breast Cancer?. Journal of Clinical Oncology, 2008, 26, 519-520. | 1.6 | 37 |
| 276 | The Signatures of Autozygosity among Patients with Colorectal Cancer. Cancer Research, 2008, 68, 2610-2621. | 0.9 | 47 |
| 277 | Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk. Cancer Research, 2008, 68, 3178-3184. | 0.9 | 104 |
| 278 | Genetic Factors: Hereditary Cancer Predisposition Syndromes. , 2008, , 171-191. | | 1 |
| 279 | AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421. | 2.5 | 30 |
| 280 | BRCA Mutations in Women with Ductal Carcinoma In situ. Clinical Cancer Research, 2007, 13, 4306-4310. | 7.0 | 29 |
| 281 | Modeling Genetic Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2637. | 7.4 | 8 |
| 282 | Single-amplicon MSH2 A636P Mutation Testing in Ashkenazi Jewish Patients With Colorectal Cancer. Annals of Surgery, 2007, 245, 560-565. | 4.2 | 11 |
| 283 | RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200. | 6.2 | 217 |
| 284 | Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology, The, 2007, 8, 26-34. | 10.7 | 220 |
| 285 | Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine, 2007, 357, 154-162. | 27.0 | 222 |
| 286 | The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genetics, 2007, 8, 68. | 2.7 | 8 |
| 287 | Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genetics, 2007, 39, 1338-1349. | 21.4 | 602 |
| 288 | Ethical and Legal Aspects of Cancer Genetic Testing. Seminars in Oncology, 2007, 34, 435-443. | 2.2 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. Annals of Surgical Oncology, 2007, 14, 2510-2518. | 1.5 | 82 |
| 290 | Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2007, 105, 221-228. | 2.5 | 45 |
| 291 | Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers. Breast Cancer Research, 2006, 8, R15. | 5.0 | 44 |
| 292 | Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25. | 6.3 | 295 |
| 293 | Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis, 2006, 27, 2243-2249. | 2.8 | 44 |
| 294 | Cancer Genetic Testing and Assisted Reproduction. Journal of Clinical Oncology, 2006, 24, 4775-4782. | 1.6 | 107 |
| 295 | MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Research, 2006, 66, 5104-5110. | 0.9 | 277 |
| 296 | ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology, 2006, 13, 1296-1321. | 1.5 | 41 |
| 297 | Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genetic Epidemiology, 2006, 30, 48-61. | 1.3 | 17 |
| 298 | Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284. | 5.1 | 246 |
| 299 | Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1479. | 7.4 | 328 |
| 300 | Reducing the Risk of Gynecologic Cancer in the Lynch Syndrome. New England Journal of Medicine, 2006, 354, 293-295. | 27.0 | 34 |
| 301 | The Role of Prevention in Oncology Practice: Results From a 2004 Survey of American Society of Clinical Oncology Members. Journal of Clinical Oncology, 2006, 24, 2948-2957. | 1.6 | 42 |
| 302 | Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2311-2313. | 2.5 | 60 |
| 303 | Preimplantation Genetic Diagnosis for Cancer Syndromes. JAMA - Journal of the American Medical Association, 2006, 296, 2727. | 7.4 | 77 |
| 304 | ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Journal of Clinical Oncology, 2006, 24, 4642-4660. | 1.6 | 214 |
| 305 | BRCA Mutation Frequency and Penetrance: New Data, Old Debate. Journal of the National Cancer Institute, 2006, 98, 1675-1677. | 6.3 | 39 |
| 306 | Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 156. | 4.9 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Value of Immunohistochemical Detection of DNA Mismatch Repair Proteins in Predicting Germline Mutation in Hereditary Colorectal Neoplasms. American Journal of Surgical Pathology, 2005, 29, 96-104. | 3.7 | 136 |
| 308 | Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecologic Oncology, 2005, 96, 21-24. | 1.4 | 35 |
| 309 | Germline mutations ofAXIN2are not associated with nonsyndromic colorectal cancer. Human Mutation, 2005, 25, 498-500. | 2.5 | 14 |
| 310 | Colorectal cancer risk in individuals with biallelic or monoallelic mutations ofMYH. International Journal of Cancer, 2005, 114, 505-507. | 5.1 | 56 |
| 311 | Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer, 2005, 117, 988-991. | 5.1 | 152 |
| 312 | Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2. Cancer, 2005, 103, 44-51. | 4.1 | 132 |
| 313 | Ovarian carcinoma screening in women at intermediate risk. Cancer, 2005, 104, 314-320. | 4.1 | 23 |
| 314 | The TP53 mutational spectrum and frequency of CHEK2*1100delC in Liâ€“Fraumeni-like kindreds. Familial Cancer, 2005, 4, 177-181. | 1.9 | 31 |
| 315 | Combined Genetic Assessment of Transforming Growth Factor-Î² Signaling Pathway Variants May Predict Breast Cancer Risk. Cancer Research, 2005, 65, 3454-3461. | 0.9 | 83 |
| 316 | Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute, 2005, 97, 1382-1384. | 6.3 | 80 |
| 317 | Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Human Molecular Genetics, 2005, 14, 555-563. | 2.9 | 109 |
| 318 | Prevention and Management of Hereditary Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1656-1663. | 1.6 | 152 |
| 319 | Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study. Journal of Clinical Oncology, 2005, 23, 7491-7496. | 1.6 | 408 |
| 320 | Hereditary Cancer Predisposition Syndromes. Journal of Clinical Oncology, 2005, 23, 276-292. | 1.6 | 534 |
| 321 | Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer. Journal of the National Cancer Institute, 2004, 96, 68-70. | 6.3 | 71 |
| 322 | MSH6 Mutations in Hereditary Nonpolyposis Colon Cancer: Another Slice of the Pie. Journal of Clinical Oncology, 2004, 22, 4449-4451. | 1.6 | 12 |
| 323 | BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clinical Cancer Research, 2004, 10, 2918-2921. | 7.0 | 156 |
| 324 | TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies. Journal of Clinical Oncology, 2004, 22, 756-758. | 1.6 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Localization of Cancer Susceptibility Genes by Genome-wide Single-Nucleotide Polymorphism Linkage-Disequilibrium Mapping. Cancer Research, 2004, 64, 8116-8125. | 0.9 | 12 |
| 326 | Breast MRI for Women With Hereditary Cancer Risk. JAMA - Journal of the American Medical Association, 2004, 292, 1368. | 7.4 | 45 |
| 327 | The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks. JAMA - Journal of the American Medical Association, 2004, 292, 1469. | 7.4 | 228 |
| 328 | Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. Cancer Research, 2004, 64, 5051-5053. | 0.9 | 51 |
| 329 | A636P testing in Ashkenazi Jews. Familial Cancer, 2004, 3, 223-227. | 1.9 | 7 |
| 330 | Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 2004, 3, 259-264. | 1.9 | 36 |
| 331 | The genetics of familial lymphomas. Current Oncology Reports, 2004, 6, 380-387. | 4.0 | 9 |
| 332 | No major association between TGFBR1*6A and prostate cancer. BMC Genetics, 2004, 5, 28. | 2.7 | 14 |
| 333 | A636P is Associated with Early-Onset Colon Cancer in Ashkenazi Jews. Journal of the American College of Surgeons, 2003, 196, 222-225. | 0.5 | 26 |
| 334 | Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic Oncology, 2003, 89, 281-287. | 1.4 | 130 |
| 335 | Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations. Cancer, 2003, 97, 1601-1608. | 4.1 | 90 |
| 336 | MSH6 germline mutations are rare in colorectal cancer families. International Journal of Cancer, 2003, 107, 571-579. | 5.1 | 53 |
| 337 | Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leukemia Research, 2003, 27, 841-851. | 0.8 | 16 |
| 338 | Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics, 2003, 4, 1. | 2.1 | 106 |
| 339 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research, 2003, 6, R8-R17. | 5.0 | 262 |
| 340 | BRCA1 and BRCA2 Germline Mutations in Lymphoma Patients. Leukemia and Lymphoma, 2003, 44, 127-131. | 1.3 | 8 |
| 341 | TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies. Journal of Clinical Oncology, 2003, 21, 3236-3243. | 1.6 | 104 |
| 342 | Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations. Journal of Clinical Oncology, 2003, 21, 4222-4227. | 1.6 | 199 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. Journal of the National Cancer Institute, 2003, 95, 1548-1551. | 6.3 | 183 |
| 344 | BLM Heterozygosity and the Risk of Colorectal Cancer. Science, 2002, 297, 2013-2013. | 12.6 | 174 |
| 345 | Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753. | 1.6 | 20 |
| 346 | Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779. | 6.3 | 318 |
| 347 | Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615. | 27.0 | 1,363 |
| 348 | Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology, 2002, 20, 1260-1268. | 1.6 | 395 |
| 349 | Considerations in genetic counseling for inherited breast cancer predisposition. Seminars in Radiation Oncology, 2002, 12, 362-370. | 2.2 | 0 |
| 350 | Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes and Cancer, 2002, 33, 114-122. | 2.8 | 59 |
| 351 | Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clinical Cancer Research, 2002, 8, 3776-81. | 7.0 | 116 |
| 352 | Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clinical Cancer Research, 2002, 8, 3813-9. | 7.0 | 29 |
| 353 | Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1579-85. | 2.5 | 74 |
| 354 | Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genetics in Medicine, 2001, 3, 422-425. | 2.4 | 17 |
| 355 | Risk of Endometrial Carcinoma Associated with BRCA Mutation. Gynecologic Oncology, 2001, 80, 395-398. | 1.4 | 147 |
| 356 | Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes. Cancer, 2000, 89, 383-390. | 4.1 | 97 |
| 357 | Genetic Prognostic Markers for Colorectal Cancer. New England Journal of Medicine, 2000, 342, 124-125. | 27.0 | 25 |
| 358 | Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations. Journal of the National Cancer Institute, 1999, 91, 2112-2117. | 6.3 | 167 |
| 359 | The APC I1307K allele and breast cancer risk. Nature Genetics, 1998, 20, 13-14. | 21.4 | 65 |
| 360 | Involvement ofBCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. , 1998, 23, 323-327. | | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388. | 6.2 | 150 |
| 362 | Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma. Blood, 1998, 92, 234-240. | 1.4 | 308 |
| 363 | A family with three germline mutations in BRCAl and BRCA2. Clinical Genetics, 1998, 54, 215-218. | 2.0 | 13 |
| 364 | Familial Hodgkin's and Non-Hodgkin's Lymphoma: Different Patterns in First-Degree Relatives. Leukemia and Lymphoma, 1997, 27, 503-507. | 1.3 | 12 |
| 365 | New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet, The, 1997, 350, 117-118. | 13.7 | 17 |
| 366 | Prevalence of Recurring BRCA Mutations Among Ashkenazi Jewish Women with Breast Cancer. Genetic Testing and Molecular Biomarkers, 1997, 1, 47-51. | 1.7 | 44 |
| 367 | Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83. | 21.4 | 630 |
| 368 | Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128. | 21.4 | 282 |
| 369 | Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genetics, 1996, 13, 241-244. | 21.4 | 162 |
| 370 | The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics, 1996, 14, 188-190. | 21.4 | 375 |
| 371 | BCL6 Gene Rearrangement and Other Cytogenetic Abnormalities in Diffuse Large Cell Lymphoma. Leukemia and Lymphoma, 1995, 20, 85-89. | 1.3 | 30 |
| 372 | Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma. New England Journal of Medicine, 1994, 331, 74-80. | 27.0 | 375 |
| 373 | Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 1993, 7, 1-7. | 2.8 | 44 |
| 374 | Chromosome Analysis in the Management of Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1992, 7, 275-282. | 1.3 | 21 |
| 375 | Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. American Journal of Medicine, 1991, 90, 328-337. | 1.5 | 29 |
| 376 | Chromosomal Aberrations in Non-Hodgkinâ€™s Lymphoma: Biologic and Clinical Correlations. Hematology/Oncology Clinics of North America, 1991, 5, 853-869. | 2.2 | 64 |
| 377 | Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes and Cancer, 1991, 3, 189-201. | 2.8 | 167 |
| 378 | Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosomes and Cancer, 1991, 3, 294-299. | 2.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral t-cell lymphomas and lymphomas of uncertain lineage, including 12 Ki-1 positive lymphomas. Genes Chromosomes and Cancer, 1990, 2, 27-35. | 2.8 | 50 |
| 380 | 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. British Journal of Haematology, 1989, 72, 178-183. | 2.5 | 97 |
| 381 | Nonrandom chromosomal aberrations are associated with sites of tissue involvement in non-Hodgkin's lymphoma. Cancer Genetics and Cytogenetics, 1989, 37, 85-93. | 1.0 | 21 |